StabiCaps™
For stable softgels
StabiCaps™ is a specialized gelatin solution engineered to stabilize softgels by minimizing cross-linking, even with reactive fills.
Softgels are among the fastest-growing dosage formats across healthcare. Producing them can be challenging, with cross-linking impairing shell stability. Coming with optimal physicochemical characteristics, StabiCaps is the proven solution for more stable softgels. This patented gelatin solution helps to limit cross-linking, enabling the formulation of robust, long-lasting pharmaceutical and nutraceutical softgels, even with reactive fillings.
Softgels are among the fastest-growing dosage formats across healthcare. Producing them can be challenging, with cross-linking impairing shell stability. Coming with optimal physicochemical characteristics, StabiCaps is the proven solution for more stable softgels. This patented gelatin solution helps to limit cross-linking, enabling the formulation of robust, long-lasting pharmaceutical and nutraceutical softgels, even with reactive fillings.
Benefits
StabiCaps excels on three main fronts
Optimized production
Shorter maturation and drying time.
Stable softgels
Full protection of active pharmaceutical ingredients (APIs), with optimal behavior in the presence of cross-linkers.
Elevated portfolio
Optimal shell stability, shelf-life, dissolution, and API release.
Resources
Related
The importance of gelatin in pharmaceutical and medical applications
Darling Ingredients health brand Rousselot receives US patent for gelatin technology that improves softgel capsule stability and efficacy
Rousselot secures Brazilian patent for advanced softgel capsule technology Stabicaps
Innovation
A patented solution
The patent has been granted by the European Patent Office (EPO). Rousselot has validated the patent in the following European countries: Belgium, Germany, France, Italy, Great Britain, The Netherlands, Norway and Spain.
- The reference to the granted patent in the European countries is EP3487486B1. Priority Date: 22 July 2016. Date of publication of granted in Europe: Feb 9, 2022.
The patent has been issued (granted) by the US Patent and Trademark Office.
- The reference to the granted patent in the US is US11795489B2. Priority Date: 22 July 2016. Date of publication of granted patent: Oct 24, 2023.